Lerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterolemia
Key result
Monthly lerodalcibep-liga reduces LDL-C by up to ~65% in patients with hypercholesterolemia.
Why the study?
Does lerodalcibep-liga reduce LDL-C in patients with hypercholesterolemia?
Key Points
- To review the pharmacology, clinical efficacy, safety, and therapeutic role of lerodalcibep-liga among PCSK9-directed therapies for hypercholesterolemia.
- Searched PubMed, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov through August 2026 for clinical trials of lerodalcibep-liga.
- Evaluated peer-reviewed publications and conference abstracts encompassing one phase 1 study, two phase 2 trials, and six phase 3 trials.
- Monthly subcutaneous lerodalcibep-liga reduced LDL-C by approximately 50% to 65% across patients with heterozygous familial hypercholesterolemia or high cardiovascular risk, with reductions sustained through 72 weeks in an open-label extension.
- Therapy also reduced apolipoprotein B, non-HDL-C, and lipoprotein(a) with acceptable tolerability, though injection-site reactions were more frequent than with placebo.
- Evidence of cardiovascular benefit remains preliminary, as lerodalcibep-liga has not yet been evaluated in a dedicated, adequately powered cardiovascular outcomes trial.
Structured PICO
Does lerodalcibep-liga reduce LDL-C in patients with hypercholesterolemia?
P
Population
Review of clinical trials evaluating lerodalcibep-liga in patients with hypercholesterolemia, including those with HeFH or high cardiovascular risk.
I
Intervention
Lerodalcibep-liga monthly subcutaneous injection
C
Comparator
Placebo or other PCSK9-directed therapies (alirocumab, evolocumab)
O
Outcome
Low-density lipoprotein cholesterol (LDL-C) reductionsurrogate
Limitations
- Direct comparative evidence remains limited
- Cardiovascular benefit has not been confirmed in a dedicated, adequately powered cardiovascular outcomes trial
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This hopefully gives doctors a more practical PCSK9 antagonist that's small volume, can be administered monthly, and is an alternative to the every 2 week injection of monoclonal antibodies and probably more effective in LDL cholesterol–lowering compared to the small interfering RNA medicines.”
“We saw no evidence of attenuation in LDL lowering effect for patients treated up to 2.4 years. Possible advantages [of lerodalcibep] are once-monthly low-volume dosing and stability at ambient temperatures. We can argue that more competition in the space is actually great news for our patients. The more availability that we have, that will help to drive down costs and improve access.”
“Given that the therapy is expected to be administered for years, a longer analysis is needed to exclude the concern that a small percentage of neutralizing antidrug antibodies could reduce the efficacy.”
Implication
Lerodalcibep-liga provides potent LDL-C lowering of 50-65% via monthly injection, offering an additional PCSK9-targeted option, though lacking dedicated cardiovascular outcomes data.
Abstract
OBJECTIVE: To critically review the pharmacology, clinical efficacy, safety, and potential therapeutic role of lerodalcibep-liga within the expanding landscape of proprotein convertase subtilisin/kexin type 9 (PCSK9)-directed therapies for patients with hypercholesterolemia. DATA SOURCES: PubMed, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched through August 2026. STUDY SELECTION AND DATA EXTRACTION: Clinical trials evaluating lerodalcibep-liga in patients with hypercholesterolemia were included. Full-text peer-reviewed publications underwent detailed evaluation; conference abstracts and posters were summarized descriptively. The search identified one phase 1 study, two phase 2 trials, and six phase 3 trials. DATA SYNTHESIS: Monthly subcutaneous lerodalcibep-liga produced low-density lipoprotein cholesterol (LDL-C) reductions of approximately 50% to 65% in patients with heterozygous familial hypercholesterolemia (HeFH), established cardiovascular disease, or high cardiovascular risk. Reductions in apolipoprotein B, non-high-density lipoprotein cholesterol, and lipoprotein(a) were also reported. Low-density lipoprotein cholesterol lowering was maintained through 72 weeks in an open-label extension. Treatment was generally well tolerated, although injection-site reactions occurred more frequently than with placebo.Relevance to patient care and clinical practice in comparison with existing drugs:Lerodalcibep-liga provides potent LDL-C lowering through a fixed, small-volume, once-monthly self-administered injection. Its efficacy is broadly comparable with other PCSK9-directed therapies, but direct comparative evidence remains limited. Analyses suggested a potential cardiovascular benefit, but this finding has not been confirmed in a dedicated, adequately powered cardiovascular outcomes trial. CONCLUSIONS: Lerodalcibep-liga is an additional potent injectable PCSK9-directed treatment for adults requiring substantial LDL-C reduction, including those with HeFH. However, alirocumab or evolocumab may remain preferable when demonstrated cardiovascular event reduction is a major consideration in treatment selection.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Alashqar et al. (2026) conducted a review in Hypercholesterolemia. Lerodalcibep-liga vs. Placebo was evaluated on Low-density lipoprotein cholesterol (LDL-C) reduction. Monthly subcutaneous lerodalcibep-liga produced LDL-C reductions of approximately 50% to 65% in patients with hypercholesterolemia.